KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to $2.5 billion.

  • Teva Pharmaceutical Industries' Accounts Payables rose 1488.88% to $2.5 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $2.5 billion, marking a year-over-year increase of 1488.88%. This contributed to the annual value of $2.5 billion for FY2025, which is 1488.88% up from last year.
  • As of Q4 2025, Teva Pharmaceutical Industries' Accounts Payables stood at $2.5 billion, which was up 1488.88% from $2.4 billion recorded in Q3 2025.
  • Teva Pharmaceutical Industries' 5-year Accounts Payables high stood at $2.6 billion for Q4 2023, and its period low was $1.5 billion during Q3 2021.
  • Its 5-year average for Accounts Payables is $2.1 billion, with a median of $2.3 billion in 2023.
  • In the last 5 years, Teva Pharmaceutical Industries' Accounts Payables soared by 3944.95% in 2023 and then plummeted by 1533.44% in 2024.
  • Quarter analysis of 5 years shows Teva Pharmaceutical Industries' Accounts Payables stood at $1.7 billion in 2021, then rose by 11.92% to $1.9 billion in 2022, then skyrocketed by 37.89% to $2.6 billion in 2023, then fell by 15.33% to $2.2 billion in 2024, then grew by 14.89% to $2.5 billion in 2025.
  • Its last three reported values are $2.5 billion in Q4 2025, $2.4 billion for Q3 2025, and $2.5 billion during Q2 2025.